1. Multiplex Autoantibody Detection in Patients with Autoimmune Polyglandular Syndromes
- Author
-
Marina Yukina, Ekaterina A. Troshina, Nurana Nuralieva, Dmitry A. Gryadunov, M A Filippova, and E. N. Savvateeva
- Subjects
0301 basic medicine ,Male ,Microarray ,autoantibodies ,medicine.disease_cause ,Autoantigens ,Autoimmunity ,0302 clinical medicine ,Autoimmune Polyglandular Syndrome ,Medicine ,Multiplex ,Biology (General) ,Polyendocrinopathies, Autoimmune ,Spectroscopy ,biology ,General Medicine ,Middle Aged ,Computer Science Applications ,multiplex assay ,Chemistry ,Organ Specificity ,Interferon Type I ,Female ,Antibody ,microarray ,Adult ,Adolescent ,QH301-705.5 ,autoimmune polyglandular syndrome ,030209 endocrinology & metabolism ,Interferon alpha-2 ,Endocrine System Diseases ,Sensitivity and Specificity ,Catalysis ,Article ,Inorganic Chemistry ,03 medical and health sciences ,Young Adult ,Endocrine system ,Humans ,In patient ,Physical and Theoretical Chemistry ,Molecular Biology ,QD1-999 ,business.industry ,Interleukins ,Organic Chemistry ,Autoantibody ,Microarray Analysis ,030104 developmental biology ,Immobilized Proteins ,Immunology ,biology.protein ,business - Abstract
The diagnosis of autoimmune polyglandular syndrome (APS) types 1/2 is difficult due to their rarity and nonspecific clinical manifestations. APS-1 development can be identified with assays for autoantibodies against cytokines, and APS-2 development with organ-specific antibodies. In this study, a microarray-based multiplex assay was proposed for simultaneous detection of both organ-specific (anti-21-OH, anti-GAD-65, anti-IA2, anti-ICA, anti-TG, and anti-TPO) and APS-1-specific (anti-IFN-ω, anti-IFN-α-2a, and anti-IL-22) autoantibodies. Herein, 206 serum samples from adult patients with APS-1, APS-2, isolated autoimmune endocrine pathologies or non-autoimmune endocrine pathologies and from healthy donors were analyzed. The prevalence of autoantibodies differed among the groups of healthy donors and patients with non-, mono- and multi-endocrine diseases. APS-1 patients were characterized by the presence of at least two specific autoantibodies (specificity 99.5%, sensitivity 100%). Furthermore, in 16 of the 18 patients, the APS-1 assay revealed triple positivity for autoantibodies against IFN-ω, IFN-α-2a and IL-22 (specificity 100%, sensitivity 88.9%). No anti-cytokine autoantibodies were found in the group of patients with non-APS-1 polyendocrine autoimmunity. The accuracy of the microarray-based assay compared to ELISA for organ-specific autoantibodies was 88.8–97.6%. This multiplex assay can be part of the strategy for diagnosing and predicting the development of APS.
- Published
- 2021